Positive Margin Rate Following Transoral Surgery in T2-T3 Laryngeal Carcinoma - a Systematic Review and Meta-Analysis.

Oral OncolAug 12, 2026 (epub)
Clinical ResearchOtolaryngology (ENT)Oncology (Medical)General Surgery

Sebastiaan W R Dalmeijer, Agatha S Baidun, Elisabeth V Sjogren et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the positive margin rate following transoral endoscopic surgery in 3,281 patients with T2-T3 laryngeal carcinoma. The overall positive margin rate was found to be 22.0% (95% CI 17.6 - 27.3). The study also assessed the impact of margin status on oncological outcomes, revealing mixed results across the included studies.

Key findings

  • The positive margin rate for T2-T3 laryngeal carcinoma was 22.0%.
  • Stratified positive margin rates were 22.4% for T2 tumors and 30.8% for T3 tumors.
  • Three out of eight studies indicated a significant association between positive margins and worse oncological outcomes.

Why it matters

Understanding the positive margin rate in transoral endoscopic surgery for laryngeal carcinoma is crucial, as it may influence treatment decisions and patient prognostication. Clinicians should be aware of the potential implications of margin status on oncological outcomes.

Source

PubMed · PMID 42585753

Published in Oral Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.